Opus Genetics (IRD) Loans and Notes Receivables (2010 - 2019)
Opus Genetics (IRD) reported Loans and Notes Receivables of $50000.0 for Q4 2019, up 970.43% on a QoQ basis from $4671.0 in Q2 2012.
Opus Genetics (IRD) has 4 years of Loans and Notes Receivables data on file, last reported at $50000.0 in Q4 2019.
- Quarterly Loans and Notes Receivables changed N/A year-over-year to $50000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $50000.0 (changed N/A YoY) and the FY2019 annual result came in at $50000.0, changed N/A from the prior year.
- Loans and Notes Receivables grew to $50000.0 in Q4 2019 per IRD's latest filing, from $4671.0 in the prior quarter.
- Across five years, Loans and Notes Receivables topped out at $50000.0 in Q4 2019 and bottomed at $50000.0 in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Loans & Notes Receiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 50,000.00 |
| Jun 30, 2012 | 4,671.00 |
| Mar 31, 2012 | 11,676.00 |
| Dec 31, 2011 | 18,682.00 |
| Sep 30, 2011 | 25,688.00 |
| Jun 30, 2011 | 28,023.00 |
| Dec 31, 2010 | 28,023.00 |